An interventional study of Episodic Future Thinking (EFT) and Episodic Recent Thinking (ERT) in Cigarette Smoking Behavior, sponsored by Virginia Polytechnic Institute and State University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University — 3 open to participants now, 3 under way, none of them phase 3. Cigarette Smoking · Virginia Polytechnic Institute and State University.
Among the 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University, this one is the 6th largest by planned enrollment, is one of 2 that started in 2026, is one of 14 with no phase, and was the 14th registered.
477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.
Browse Cigarette Smoking studies →3 of the 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University are open now, in 1 country. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 21+
Virginia Polytechnic Institute and State University · Sites in United States
Ages 21+
By country, each count listing its studies:
Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 134 is above the median of 96 across 407 interventional studies indexed under Cigarette Smoking.
Median enrollment 87 across the 15 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Virginia Polytechnic Institute and State University is the lead sponsor of 127 studies on the registry; 28 are open to participants now.
1 of the studies in Cigarette Smoking by Virginia Polytechnic Institute and State University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07158749Virginia Polytechnic Institute and State UniversityGeneralized and Domain-Specific Episodic Thinking for Smoking Cessation | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cigarette smoking remains common, particularly in rural areas, despite ample evidence that smoking causes cancer and respiratory disease. Successful smoking cessation yields the majority of its health benefits (e.g., avoidance of lung cancer) after years of sustained behavioral change; however, people who smoke cigarettes tend to show elevated rates of delay discounting (i.e., devaluation of delayed outcomes) and a bias for immediate gratification. The overall goal of this project is to develop different versions of an episodic future thinking intervention (i.e., visualization of the future) and test their feasibility and efficacy for smoking cessation in rural and urban populations.
Cigarette smoking causes more than a dozen cancers, including cancers of the head and neck, colon, bladder, and lung. Although quitting smoking drastically reduces the risk of cancer mortality, rates of cessation are low, particularly in rural areas and other communities. Current evidence-based treatments for smoking cessation have made progress, but substantial room for innovation remains and novel strategies are needed. Successful smoking cessation may be considered, in part, an intertemporal choice between continuing to smoke and achieving the delayed health benefits associated with quitting (e.g., avoidance of lung cancer). Thus, quitting requires one's behavior to be sufficiently motivated by future outcomes. Unfortunately, robust cross-sectional and longitudinal evidence indicates that people who smoke cigarettes show elevated delay discounting, or a bias for immediate gratification. Prior research shows that delay discounting predicts treatment failure and relapse in smoking cessation. These findings suggest that delay discounting often prevents successful quitting because the health benefits of cessation (e.g., avoiding cancer) are too delayed to motivate sustained behavioral change. Thus, delay discounting is a therapeutic target in smoking cessation, where interventions that increase valuation of future outcomes may facilitate quitting. Episodic future thinking (EFT) is one such scalable intervention that is designed to shift time perspective and reduce bias for immediate gratification by promoting vivid and frequent visualization of a broad range of personally significant future events (e.g., weddings, birthdays, spending time with loved ones). In laboratory studies, research has shown that this form of generalized EFT in cigarette smokers reduces delay discounting and motivation to smoke (i.e., cigarette consumption, craving, and valuation). Moreover, strong preliminary evidence suggests that cancer-related EFT, a novel form of the intervention that involves visualizing the future experience of smoking-related lung cancer, may be more efficacious for reducing urges to smoke than the generalized form. The proposed trial will adapt both forms of EFT (generalized and cancer-related) for clinical use in smoking cessation. Remote intervention delivery and outcomes assessment (breath carbon monoxide and number of cigarettes smoked per day) will be used to minimize clinical burden and increase intervention reach and access, including in rural populations who often lack access to evidence-based treatments for smoking cessation. In an eight-week proof-of-concept trial, participants will be prompted to engage in EFT or control episodic thinking multiple times per day and during acute craving episodes. Specific Aims 1 and 2 will examine the feasibility and efficacy, respectively, of generalized and cancer-related EFT to reduce smoking. An Exploratory Aim will investigate the potential moderating role of income, education, sex, and other characteristics (e.g., baseline delay discounting, cigarettes/day) in the effects of EFT on smoking outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Generalized EFT group will identify positive events that may occur at 6 future time points (1 month to 5 years). These may include a broad range of personally significant milestones (e.g., weddings, birthdays) or other events that participants are looking forward to (e.g., spending time with loved ones). Participants will also generate vivid text descriptions, or cues (transcribed in their own words), to prompt EFT in the natural environment. These cues, including emotional impacts, will be elicited using standardized questions: Who are you with? What are you doing? Where are you? How are you feeling? Participants will be prompted to engage in Generalized EFT in the natural environment.
Behavioral: Episodic Future Thinking (EFT) · Behavioral: Generalized episodic thinking
The Domain-Specific EFT group will complete an identical interview as the Generalized EFT group to identify positive future events, with one exception. Following initial cue generation, participants will be provided with descriptions of lung cancer symptoms (e.g., painful breathing; extreme fatigue; coughing up blood, phlegm, or mucus) and will be asked to visualize and include details related to this experience and their emotional impact in their revised cues. Thus, cancer-related symptoms occur in the context of otherwise positive, personally significant events to further highlight the impact of the diagnosis and to be consistent with Generalized EFT. Participants will be prompted to engage in Domain-Specific EFT in the natural environment.
Behavioral: Episodic Future Thinking (EFT) · Behavioral: Domain-specific episodic thinking
The Generalized ERT interview will be identical to the one described for Generalized EFT, except participants will describe positive events they experienced in the last week. Participants will be prompted to engage in Generalized ERT in the natural environment.
Behavioral: Episodic Recent Thinking (ERT) · Behavioral: Generalized episodic thinking
The Domain-Specific ERT interview will be identical to the one described for Domain-Specific EFT, except participants will describe positive events they experienced in the last week and will subsequently add detail as though they were experiencing symptoms of lung cancer. Participants will be prompted to engage in Domain-Specific ERT in the natural environment.
Behavioral: Episodic Recent Thinking (ERT) · Behavioral: Domain-specific episodic thinking
Participants will engage in EFT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
Participants will engage in ERT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
Content of the episodic thinking intervention will experiencing the symptoms of lung cancer during a broad range of personally meaningful, otherwise positive, events (e.g., social events, celebrations, spending times with friends and family).
Content of the episodic thinking intervention will include a broad range of personally meaningful, positive, events (e.g., social events, celebrations, spending times with friends and family).
Cigarettes smoked per day
A timeline followback questionnaire will be used to assess the number of cigarettes smoked per day. Lower values reflect better outcomes.
Time frame: From Week 0 to the end of treatment at 8 weeks
Other tobacco/nicotine product use per day
A timeline followback questionnaire will be used to assess the number of times participants use other tobacco/nicotine products per day (excluding cigarettes and nicotine patch). Lower values reflect better outcomes.
Time frame: From Week 0 to the end of treatment at 8 weeks
7-day point prevalence cigarette abstinence
A timeline followback questionnaire will be used to assess cigarette abstinence status (binary) over the final seven days of the intervention.
Time frame: Week 8
Nicotine patch adherence (feasibility outcome)
A timeline followback questionnaire will be used to assess frequency of use of the study-provided nicotine patches. Higher values reflect better adherence to nicotine replacement therapy.
Time frame: From Week 1 to the end of treatment at 8 weeks
Depressive symptoms (feasibility outcome)
Depression symptoms over the last 2 weeks will be assessed using the Patient Health Questionnaire-8 (PHQ-8). Total scores on this scale range from 0 (no depressive symptoms) to 24 (severe depressive symptoms).
Time frame: From Week 0 to the end of treatment at 8 weeks
Anxiety symptoms (feasibility outcome)
Anxiety symptoms over the last 2 weeks will be assessed using the Generalized Anxiety Disorder-7 (GAD-7) questionnaire. Total scores on this scale range from 0 (no anxiety symptoms) to 21 (severe anxiety symptoms).
Time frame: From Week 0 to the end of treatment at 8 weeks
Episodic thinking adherence (feasibility outcome)
Adherence to the episodic thinking interventions will be measured as the percentage of daily cue prompts that participants access.
Time frame: From Week 1 to the end of treatment at 8 weeks
Perceived convenience (feasibility outcome)
Participants will evaluate perceived convenience of the intervention, both overall and its individual components, using visual analog scales with ratings ranging from 0 to 100. Higher ratings reflect greater convenience
Time frame: From Week 1 to the end of treatment at 8 weeks
Perceived helpfulness (feasibility outcome)
Participants will evaluate perceived helpfulness of the intervention, both overall and its individual components, using visual analog scales with ratings ranging from 0 to 100. Higher ratings reflect greater helpfulness.
Time frame: From Week 1 to the end of treatment at 8 weeks
Plan to share: Yes — All de-identified study data that are included in publication results will be shared using a project-specific url.
Supporting information: Statistical analysis plan, Informed consent form, Analytic code
Time frame: Study data and supporting information will be available beginning 3 months and ending 5 years after the publication of results.
Access criteria: All shared deidentified study data and supporting information will be available without restriction via a project-specific url.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 9 months is below that.
Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion May 2027 → Jun 2027 and completion May 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Virginia Polytechnic Institute and State University →